Literature DB >> 26235182

The diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives.

Paraskevi Boura1, Stylianos Loukides1, Dimitra Grapsa1, Apostolos Achimastos1, Konstantinos Syrigos1.   

Abstract

In recent years, there is growing research interest for the biological role of adipose tissue-derived bioactive factors, mainly including adipokines, in various forms of cancer. Adiponectin (APN) is the most abundant circulating adipokine, and a key mediator of several cancer-related processes, such as cell proliferation, apoptosis, regulation of tumor cell invasion and angiogenesis. In this review we summarize and critically discuss the published literature on the diverse roles of APN in non-small-cell lung cancer, including its implication in lung cancer development, its use as a diagnostic and prognostic biomarker, and its correlation with cancer-related cachexia. The main challenges and future perspectives, mainly with regard to the potential development of APN-targeted therapeutic agents in cancer therapeutics, are also briefly presented and discussed.

Entities:  

Keywords:  adipokines; adiponectin; adipose tissue; cancer cachexia; non-small-cell lung cancer

Mesh:

Substances:

Year:  2015        PMID: 26235182     DOI: 10.2217/fon.15.96

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  9 in total

1.  The clinical significance of serum adipocytokines level in patients with lung cancer.

Authors:  Fanfan Li; Yanan Cao; Jingjing Li; Cong Gao; Xiang Dong; Pengfei Ren; Chenxu Meng; Chanjuan Chen
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

Review 2.  The Adipokines in Cancer Cachexia.

Authors:  Michele Mannelli; Tania Gamberi; Francesca Magherini; Tania Fiaschi
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923

3.  The Role of Obesity in Early and Long-Term Outcomes after Surgical Excision of Lung Oligometastases from Colorectal Cancer.

Authors:  Francesco Londero; Orlando Parise; William Grossi; Angelo Morelli; Gianluca Masullo; Michele Bartoletti; Cecilia Tetta; Ugolino Livi; Jos G Maessen; Sandro Gelsomino
Journal:  J Clin Med       Date:  2020-11-05       Impact factor: 4.241

4.  Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study.

Authors:  Ji Hyun Lee; Sujin Hyung; Jeeyun Lee; Sang-Hee Choi
Journal:  J Immunother Cancer       Date:  2022-08       Impact factor: 12.469

5.  The prognostic value of serum and bronchoalveolar lavage levels of adiponectin in advanced non-small-cell lung cancer.

Authors:  Paraskevi Boura; Dimitra Grapsa; Stylianos Loukides; Maria Angelidou; Konstantina Tsakanika; Nikolaos Syrigos; Ioannis Gkiozos
Journal:  Lung Cancer Manag       Date:  2017-11-17

Review 6.  Cardiac cachexia: hic et nunc.

Authors:  Goran Loncar; Jochen Springer; Markus Anker; Wolfram Doehner; Mitja Lainscak
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-07-01       Impact factor: 12.910

7.  Genetic variation in CDH13 gene was associated with non-small cell lung cancer (NSCLC): A population-based case-control study.

Authors:  Yingfu Li; Chuanyin Li; Qianli Ma; Yu Zhang; Yueting Yao; Shuyuan Liu; Xinwen Zhang; Chao Hong; Fang Tan; Li Shi; Yufeng Yao
Journal:  Oncotarget       Date:  2017-12-05

8.  Adiponectin Expression Is Modulated by Long-Term Physical Activity in Adult Patients Affected by Cystic Fibrosis.

Authors:  Rita Polito; Ersilia Nigro; Ausilia Elce; Maria Ludovica Monaco; Paola Iacotucci; Vincenzo Carnovale; Marika Comegna; Monica Gelzo; Federica Zarrilli; Gaetano Corso; Giuseppe Castaldo; Aurora Daniele
Journal:  Mediators Inflamm       Date:  2019-09-09       Impact factor: 4.711

Review 9.  Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors.

Authors:  Karam Khaddour; Sandra L Gomez-Perez; Nikita Jain; Jyoti D Patel; Yanis Boumber
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.